Changes in Hong Kong stocks | Chuangsheng Group Pharmaceutical-B (06628) rose more than 11% in the morning and plans to sell CDMO assets for 190 million yuan

The Zhitong Finance App learned that Chuangsheng Group Pharmaceutical-B (06628) rose by more than 11% in the morning. As of press release, it had risen 11.22% to HK$1.14, with a turnover of HK$347,700.

According to the news, Chuangsheng Group Pharmaceutical-B issued an announcement. On August 6, 2026 (after the transaction period), the seller (a wholly-owned subsidiary of the Company) signed an asset purchase agreement with the buyer Hangzhou Mingde Biomedical Technology Co., Ltd., and the seller conditionally agreed to buy CDMO assets. The total cost was RMB 190 million (which can be adjusted according to the asset purchase agreement). After the completion of Phase II, the Company will no longer have any interest in CDMO assets.

CDMO assets mainly include GMP production facilities involved in the Group's past provision of CDMO services. The transaction did not involve the sale of any intellectual property rights held by the Group in relation to its drug candidate product pipeline or its core biomanting platforms and technologies (including highly enhanced continuous bioprocessing (HiCB) platforms and cell culture medium ExcelPro CHO). After the transaction is completed, the Company will continue to generate revenue through external licensing and cooperation arrangements for core technologies related to these CDMO services.